{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:07:04Z","timestamp":1786118824789,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1097\/bor.0b013e328172dc1a","type":"journal-article","created":{"date-parts":[[2007,6,4]],"date-time":"2007-06-04T04:03:24Z","timestamp":1180929804000},"page":"364-369","source":"Crossref","is-referenced-by-count":17,"title":["New and emerging treatments for osteoporosis"],"prefix":"10.1097","volume":"19","author":[{"given":"Michael","family":"Maricic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210128","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medications","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"R2-9-20210128","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00198-003-1502-4","article-title":"Compliance with pharmacologic therapy for osteoporosis","volume":"14","author":"Yood","year":"2003","journal-title":"Osteoporos Int"},{"key":"R3-9-20210128","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","article-title":"The impact of compliance with osteoporosis therapy on fracture rates in actual practice","volume":"15","author":"Caro","year":"2004","journal-title":"Osteoporos Int"},{"key":"R4-9-20210128","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","article-title":"Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases","volume":"81","author":"Siris","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R5-9-20210128","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bone.2005.05.007","article-title":"Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis","volume":"37","author":"Epstein","year":"2005","journal-title":"Bone"},{"key":"R6-9-20210128","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00198-006-0179-x","article-title":"Compliance with drug therapy for postmenopausal osteoporosis","volume":"17","author":"Weycker","year":"2006","journal-title":"Osteoporos Int"},{"key":"R7-9-20210128","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R8-9-20210128","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"R9-9-20210128","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the Dosing Intravenous Administration Study","volume":"54","author":"Delmas","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R10-9-20210128","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ddr.10071","article-title":"Pharmacological profile of zoledronic acid: a highly potent inhibitor of bone resorption","volume":"55","author":"Green","year":"2002","journal-title":"Drug Dev Res"},{"key":"R11-9-20210128","first-page":"S368","article-title":"Mineral binding affinities and zeta potentials of bisphosphonates","volume":"17","author":"Nancollas","year":"2002","journal-title":"J Bone Miner Res"},{"key":"R12-9-20210128","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1006\/bbrc.2002.6510","article-title":"The bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts","volume":"291","author":"Viereck","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"R13-9-20210128","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in posmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"key":"R14-9-20210128","first-page":"S16","article-title":"Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: the HORIZON pivotal fracture trial","volume":"21","author":"Black","year":"2006","journal-title":"J Bone Miner Res"},{"key":"R15-9-20210128","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int"},{"key":"R16-9-20210128","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1210\/jc.2004-2364","article-title":"Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy","volume":"90","author":"Holick","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-9-20210128","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"R18-9-20210128","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.0105-2896.2005.00327.x","article-title":"Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL\u2013RANK signaling system","volume":"208","author":"Tanaka","year":"2005","journal-title":"Immunol Rev"},{"key":"R19-9-20210128","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"R20-9-20210128","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"R21-9-20210128","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"R22-9-20210128","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"R23-9-20210128","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1359\/jbmr.2001.16.2.348","article-title":"The effect of a single dose of osteoprotegerin in postmenopausalwomen","volume":"16","author":"Bekker","year":"2001","journal-title":"J Bone Miner Res"},{"key":"R24-9-20210128","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R25-9-20210128","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"R26-9-20210128","first-page":"4108","article-title":"RANK ligand inhibition with denosumab (AMG 162) increases bone mineral density in postmenopausal women after two years of treatment [abstract]","volume":"52","author":"Lewiecki","year":"2005","journal-title":"Arthritis Rheum"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0b013e328172dc1a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:41:05Z","timestamp":1786034465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-200707000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e328172dc1a","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}